<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Anaesthesiol Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Anaesthesiol Clin Pharmacol</journal-id><journal-id journal-id-type="publisher-id">JOACP</journal-id><journal-id journal-id-type="publisher-id">J Anaesthesiol Clin Pharmacol</journal-id><journal-title-group><journal-title>Journal of Anaesthesiology, Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0970-9185</issn><issn pub-type="epub">2231-2730</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9438809</article-id><article-id pub-id-type="publisher-id">JOACP-38-151</article-id><article-id pub-id-type="doi">10.4103/joacp.joacp_250_21</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to Editor</subject></subj-group></article-categories><title-group><article-title>Diffusion capacity for carbon monoxide in patients recovered from COVID-19: A useful parameter to assess pulmonary function</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Ajmer</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Nanda</surname><given-names>Chinmaya</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Mehta</surname><given-names>Yatin</given-names></name><xref rid="aff1" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Department of Cardiac Anaesthesia, Institute of Critical Care and Anesthesiology, Medanta-The Medicity, Gurugram, Haryana, India</aff><author-notes><corresp id="cor1">
<bold>Address for correspondence:</bold> Dr. Ajmer Singh, Director, Cardiac Anaesthesia, Institute of Critical Care and Anaesthesiology, Medanta-The Medicity, Sector - 38, Gurugram - 122 001, Haryana, India. E-mail: <email xlink:href="ajmersingh@yahoo.com">ajmersingh@yahoo.com</email>
</corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>15</day><month>6</month><year>2022</year></pub-date><volume>38</volume><issue>Suppl 1</issue><fpage>S151</fpage><lpage>S153</lpage><history><date date-type="received"><day>23</day><month>5</month><year>2021</year></date><date date-type="rev-recd"><day>05</day><month>7</month><year>2021</year></date><date date-type="accepted"><day>07</day><month>7</month><year>2021</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2022 Journal of Anaesthesiology Clinical Pharmacology</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions></article-meta></front><body><p>Dear Editor,</p><p>Diffusion capacity of the lungs for carbon monoxide (DL<sub>CO</sub>), in combination with spirometry and lung volumes, is indicated to evaluate the parenchymal and non-parenchymal lung diseases. The preoperative DL<sub>CO</sub> is not routinely measured in patients in most cardiac surgery units. DL<sub>CO</sub> is used to assess the severity of obstructive and restrictive lung diseases, pulmonary vascular disease, and preoperative risk. The patients surviving coronavirus disease-2019 (COVID-19) are frequently reported to have pulmonary sequelae.[<xref rid="R1" ref-type="bibr">1</xref>]</p><p>We recently encountered five patients admitted for cardiac surgery, who had contracted COVID-19 about 6&#x02013;8 months ago. Preoperative assessment of the pulmonary function included chest X-ray, high-resolution computed tomography of the chest, arterial blood gas analysis at room air, and spirometry with DL<sub>CO</sub> measurement. The DL<sub>CO</sub> was measured by SPIRO AIR<sup>&#x000ae;</sup> volumetric PFT (pulmonary function test) System (Medisoft, Sorinnes, Belgium) using a single-breath technique. The patients&#x02019; details and PFT values are shown in <xref rid="joacp_250_21-t001" ref-type="table">Table 1</xref>. There was severe impairment of DL<sub>CO</sub> and alveolar volume (Va) values (37% and 45% of predicted, respectively) in patient number one. The patient was referred for pulmonary rehabilitation and optimization of medical therapy, and was asked for a follow-up at 3 months. The remaining four patients with normal DL<sub>CO</sub> values underwent cardiac surgery uneventfully.</p><table-wrap position="float" id="joacp_250_21-t001"><label>Table 1</label><caption><p>Patient Characteristics and Pulmonary Function Test Values</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Patient 1</th><th align="center" rowspan="1" colspan="1">Patient 2</th><th align="center" rowspan="1" colspan="1">Patient 3</th><th align="center" rowspan="1" colspan="1">Patient 4</th><th align="center" rowspan="1" colspan="1">Patient 5</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">57</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">Male</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (m)</td><td align="center" rowspan="1" colspan="1">1.71</td><td align="center" rowspan="1" colspan="1">1.66</td><td align="center" rowspan="1" colspan="1">1.75</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">1.64</td></tr><tr><td align="left" rowspan="1" colspan="1">BSA (m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">2.07</td><td align="center" rowspan="1" colspan="1">1.74</td><td align="center" rowspan="1" colspan="1">2.04</td><td align="center" rowspan="1" colspan="1">1.78</td><td align="center" rowspan="1" colspan="1">1.74</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">30.8</td><td align="center" rowspan="1" colspan="1">24.0</td><td align="center" rowspan="1" colspan="1">28.1</td><td align="center" rowspan="1" colspan="1">32.5</td><td align="center" rowspan="1" colspan="1">25.3</td></tr><tr><td align="left" rowspan="1" colspan="1">H/o Smoking</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Diagnosis</td><td align="center" rowspan="1" colspan="1">Severe MR</td><td align="center" rowspan="1" colspan="1">CAD</td><td align="center" rowspan="1" colspan="1">Severe MS</td><td align="center" rowspan="1" colspan="1">Severe MR, Severe TR</td><td align="center" rowspan="1" colspan="1">CAD</td></tr><tr><td align="left" rowspan="1" colspan="1">COVID-19 Positive</td><td align="center" rowspan="1" colspan="1">Sept 2020</td><td align="center" rowspan="1" colspan="1">Aug 2020</td><td align="center" rowspan="1" colspan="1">Oct 2020</td><td align="center" rowspan="1" colspan="1">Sept 2020</td><td align="center" rowspan="1" colspan="1">Sept 2020</td></tr><tr><td align="left" rowspan="1" colspan="1">HRCT Chest</td><td align="center" rowspan="1" colspan="1">Subpleural GGO, Traction- bronchiectasis</td><td align="center" rowspan="1" colspan="1">Thickening of interlobular septae</td><td align="center" rowspan="1" colspan="1">Fibroatelectatic bands in RML</td><td align="center" rowspan="1" colspan="1">Thin atelectatic bands (both lungs)</td><td align="center" rowspan="1" colspan="1">GGO, Prominent interlobular septae (upper lobes, RML)</td></tr><tr><td align="left" rowspan="1" colspan="1">PaCO<sub>2</sub>, PaO<sub>2</sub> (room air) mmHg</td><td align="center" rowspan="1" colspan="1">45.8, 60.5</td><td align="center" rowspan="1" colspan="1">34.5, 96.8</td><td align="center" rowspan="1" colspan="1">36.2, 79.0</td><td align="center" rowspan="1" colspan="1">31.7, 95.1</td><td align="center" rowspan="1" colspan="1">33.3, 79.7</td></tr><tr><td align="left" rowspan="1" colspan="1">6 MWT (m)</td><td align="center" rowspan="1" colspan="1">Not performed</td><td align="center" rowspan="1" colspan="1">504</td><td align="center" rowspan="1" colspan="1">483</td><td align="center" rowspan="1" colspan="1">379</td><td align="center" rowspan="1" colspan="1">558</td></tr><tr><td align="left" rowspan="1" colspan="1">SpO<sub>2</sub>% (Pre, Post 6MWT)</td><td align="center" rowspan="1" colspan="1">91/--</td><td align="center" rowspan="1" colspan="1">98/96</td><td align="center" rowspan="1" colspan="1">95/94</td><td align="center" rowspan="1" colspan="1">97/94</td><td align="center" rowspan="1" colspan="1">96/94</td></tr><tr><td align="left" rowspan="1" colspan="1">Spirometry</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FVC (L, % pred)</td><td align="center" rowspan="1" colspan="1">1.93 (55)</td><td align="center" rowspan="1" colspan="1">3.24 (105)</td><td align="center" rowspan="1" colspan="1">4.06 (102)</td><td align="center" rowspan="1" colspan="1">2.34 (118)</td><td align="center" rowspan="1" colspan="1">2.75 (85)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEV1 (L, % pred)</td><td align="center" rowspan="1" colspan="1">1.66 (60)</td><td align="center" rowspan="1" colspan="1">2.45 (99)</td><td align="center" rowspan="1" colspan="1">3.24 (102)</td><td align="center" rowspan="1" colspan="1">1.89 (115)</td><td align="center" rowspan="1" colspan="1">2.35 (90)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;FEV1/FVC Ratio (%, % pred)</td><td align="center" rowspan="1" colspan="1">85.72 (113)</td><td align="center" rowspan="1" colspan="1">73.38 (98)</td><td align="center" rowspan="1" colspan="1">79.95 (103)</td><td align="center" rowspan="1" colspan="1">80.41 (104)</td><td align="center" rowspan="1" colspan="1">85.26 (111)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PEF (L/s, % pred)</td><td align="center" rowspan="1" colspan="1">7.11 (89)</td><td align="center" rowspan="1" colspan="1">8.59 (116)</td><td align="center" rowspan="1" colspan="1">7.72 (89)</td><td align="center" rowspan="1" colspan="1">4.63 (86)</td><td align="center" rowspan="1" colspan="1">6.81 (88)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MEF (L/s, % pred)</td><td align="center" rowspan="1" colspan="1">2.69 (80)</td><td align="center" rowspan="1" colspan="1">2.59 (87)</td><td align="center" rowspan="1" colspan="1">3.27 (84)</td><td align="center" rowspan="1" colspan="1">2.17 (81)</td><td align="center" rowspan="1" colspan="1">3.13 (92)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lung Volumes</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;He-VC (L)</td><td align="center" rowspan="1" colspan="1">3.64</td><td align="center" rowspan="1" colspan="1">3.2</td><td align="center" rowspan="1" colspan="1">4.12</td><td align="center" rowspan="1" colspan="1">2.94</td><td align="center" rowspan="1" colspan="1">3.36</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;He-FRC (L)</td><td align="center" rowspan="1" colspan="1">3.47</td><td align="center" rowspan="1" colspan="1">3.41</td><td align="center" rowspan="1" colspan="1">3.47</td><td align="center" rowspan="1" colspan="1">2.47</td><td align="center" rowspan="1" colspan="1">3.27</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;He-RV (L)</td><td align="center" rowspan="1" colspan="1">2.37</td><td align="center" rowspan="1" colspan="1">2.45</td><td align="center" rowspan="1" colspan="1">2.20</td><td align="center" rowspan="1" colspan="1">1.76</td><td align="center" rowspan="1" colspan="1">2.19</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;He-TLC (L)</td><td align="center" rowspan="1" colspan="1">5.92</td><td align="center" rowspan="1" colspan="1">5.57</td><td align="center" rowspan="1" colspan="1">6.21</td><td align="center" rowspan="1" colspan="1">3.82</td><td align="center" rowspan="1" colspan="1">5.42</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RV/TLC (%)</td><td align="center" rowspan="1" colspan="1">38.1</td><td align="center" rowspan="1" colspan="1">40.7</td><td align="center" rowspan="1" colspan="1">34.1</td><td align="center" rowspan="1" colspan="1">40.4</td><td align="center" rowspan="1" colspan="1">36.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Diffusion Test</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DL<sub>CO</sub> (ml/mmHg/min, % pred)</td><td align="center" rowspan="1" colspan="1">9.67 (37)</td><td align="center" rowspan="1" colspan="1">21.80 (93)</td><td align="center" rowspan="1" colspan="1">26.47 (89)</td><td align="center" rowspan="1" colspan="1">15.10 (77)</td><td align="center" rowspan="1" colspan="1">20.85 (75)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Va (L, % pred)</td><td align="center" rowspan="1" colspan="1">2.94 (45)</td><td align="center" rowspan="1" colspan="1">5.64 (91)</td><td align="center" rowspan="1" colspan="1">5.62 (81)</td><td align="center" rowspan="1" colspan="1">3.06 (72)</td><td align="center" rowspan="1" colspan="1">5.14 (76)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Kco (ml/mmHg/min/L, % pred)</td><td align="center" rowspan="1" colspan="1">3.29 (82)</td><td align="center" rowspan="1" colspan="1">3.87 (102)</td><td align="center" rowspan="1" colspan="1">4.71 (109)</td><td align="center" rowspan="1" colspan="1">4.94 (106)</td><td align="center" rowspan="1" colspan="1">4.05 (98)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;BHT (%)</td><td align="center" rowspan="1" colspan="1">10.5</td><td align="center" rowspan="1" colspan="1">10.5</td><td align="center" rowspan="1" colspan="1">10.7</td><td align="center" rowspan="1" colspan="1">11.8</td><td align="center" rowspan="1" colspan="1">10.83</td></tr></tbody></table><table-wrap-foot><fn><p>BSA: body surface area, BMI: body mass index, MR: mitral regurgitation, CAD: coronary artery disease, MS: mitral stenosis, TR: tricuspid regurgitation, HRCT: high resolution computed tomography, GGO: ground-glass opacities, RML: right middle lobe, 6 MWT: six-minute walk test, FVC: forced vital capacity, pred: predicted, FEV1: forced expiratory volume in 1 s, PEF: peak expiratory flow, MEF: maximum expiratory flow, He: Helium, FRC; functional residual capacity, RV: residual volume, TLC: total lung capacity, DL<sub>CO</sub>: Diffusion capacity for carbon monoxide, Va: alveolar volume, Kco: Transfer coefficient for carbon monoxide, BHT: breath holding time</p></fn></table-wrap-foot></table-wrap><p>Recent studies have shown that the lung is the most commonly affected organ by COVID-19.[<xref rid="R1" ref-type="bibr">1</xref>] In the initial reports from Wuhan, China, up to one-third of patients with COVID-19 developed severe pneumonia and acute respiratory distress syndrome.[<xref rid="R2" ref-type="bibr">2</xref>] The exact mechanism of lung dysfunction in recovered COVID-19 patients remains unknown. Endothelial injury and alveolar-capillary micro-thrombosis have been described as underlying mechanisms of pulmonary vascular disease in these patients. Due to the thickening of the alveolar-capillary membrane, there is reduction in both DL<sub>CO</sub> and Kco (transfer coefficient) in patients with interstitial lung disease and pulmonary fibrosis.[<xref rid="R3" ref-type="bibr">3</xref>] An isolated reduction in DL<sub>CO</sub> suggests loss of the pulmonary capillary bed from early parenchymal lung disease. In contrast to the spirometric values, DLCO is less affected by the patient&#x02019;s effort. Unpublished data from a recent study by Qin <italic toggle="yes">et al</italic>.[<xref rid="R4" ref-type="bibr">4</xref>] have shown that 44 (54%) of 81 patients had abnormal DL<sub>CO</sub> (&#x0003c;80% predicted) after 3 months of COVID-19. They also found that the patients with impaired DL<sub>CO</sub> had a higher percentage of pulmonary interstitial damage. In rehabilitating patients of severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), impairment of DL<sub>CO</sub> was the most commonly seen abnormality followed by a restrictive ventilatory defect. A recent prospective, multicenter study has shown that DL<sub>CO</sub> % predicted at 4 months after COVID-19 was the most important, independent correlate of a more severe initial disease.[<xref rid="R5" ref-type="bibr">5</xref>]</p><p>In conclusion, our case series reveals that COVID-19 survivors presenting for cardiac surgery can have impaired DL<sub>CO</sub>. Long-term studies are needed to address whether the assessment of DL<sub>CO,</sub> in addition to spirometry, should be considered in routine clinical follow-up of COVID-19 survivors.</p><sec disp-level="2"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" disp-level="2"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>F</given-names></name>
<name><surname>Yu</surname><given-names>T</given-names></name>
<name><surname>Du</surname><given-names>R</given-names></name>
<name><surname>Fan</surname><given-names>G</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>Z</given-names></name>
<etal/>
</person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1054</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Fan</surname><given-names>G</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>Z</given-names></name>
<etal/>
</person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Heckman</surname><given-names>EJ</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>GT</given-names></name>
</person-group><article-title>Pulmonary function tests for diagnosing lung disease</article-title><source>JAMA</source><year>2015</year><volume>313</volume><fpage>2278</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">26057290</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Qin</surname><given-names>W</given-names></name>
<name><surname>Chen</surname><given-names>S</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Dong</surname><given-names>F</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Hu</surname><given-names>B</given-names></name>
<etal/>
</person-group><article-title>Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 At three-month follow-up</article-title><source>Eur Respir J</source><year>2021</year><comment>in press. doi: 10.1183/13993003.03677-2020</comment></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Guler</surname><given-names>SA</given-names></name>
<name><surname>Ebner</surname><given-names>L</given-names></name>
<name><surname>Beigelman</surname><given-names>C</given-names></name>
<name><surname>Bridevaux</surname><given-names>PO</given-names></name>
<name><surname>Brutsche</surname><given-names>M</given-names></name>
<name><surname>Clarenbach</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Pulmonary function and radiological features four months after COVID-19: First results from the national prospective observational Swiss COVID-19 lung study</article-title><source>Eur Respir J</source><year>2021</year><volume>57</volume><fpage>2003690</fpage><pub-id pub-id-type="pmid">33419891</pub-id></element-citation></ref></ref-list></back></article>
